BioMarin Q3 non-GAAP diluted EPS jumps 92% to $0.23

Bitget2026/11/02 21:08

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioMarin Pharmaceutical reported a third-quarter 2026 GAAP diluted loss of $0.63 per share.
Total revenue rose 32% year over year to $1.03 billion, primarily driven by GALAFOLD and POMBILITI + OPFOLDA.
VOXZOGO’s application for hypochondroplasia has a May 30, 2027, PDUFA action date.
Full-year 2026 total revenue guidance fell to $3.8 billion–$3.9 billion, reflecting uncertainty over international customer order timing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioMarin Q3 non-GAAP diluted EPS jumps 92% to $0.23

You may also like

Crypto prices